N. Anthony Coles, Director at Cerevel Therapeutics Holdings, Inc. (CERE), sold 100,000 shares at $41.16 ($4.1M) on 2024-02-29, disclosed to the SEC on 2024-03-04.
Scheduled sale ($4.1M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.16 | 50,000 | $2.1M | 50.0% |
| 2 | $41.16 | 50,000 | $2.1M | 50.0% |
| Total | $41.16 avg | 100,000 | $4.1M | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |